{"organizations": [], "uuid": "63512490ab6d7023a5729ba33338e6be890296b3", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews\r", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-syros-pharmaceuticals-reports-q1-l/brief-syros-pharmaceuticals-reports-q1-loss-per-share-of-0-48-idUSASC0A1DZ", "country": "US", "domain_rank": 408, "title": "BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share Of $0.48", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-05-10T14:38:00.000+03:00", "replies_count": 0, "uuid": "63512490ab6d7023a5729ba33338e6be890296b3"}, "author": "", "url": "https://www.reuters.com/article/brief-syros-pharmaceuticals-reports-q1-l/brief-syros-pharmaceuticals-reports-q1-loss-per-share-of-0-48-idUSASC0A1DZ", "ord_in_thread": 0, "title": "BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share Of $0.48", "locations": [], "entities": {"persons": [{"name": "sha", "sentiment": "negative"}], "locations": [], "organizations": [{"name": "brief-syros pharmaceuticals reports", "sentiment": "negative"}, {"name": "dec", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "thomson reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}, {"name": "syros pharmaceuticals inc", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "May 10, 2018 / 11:39 AM / Updated 13 minutes ago BRIEF-Syros Pharmaceuticals Reports Q1 Loss Per Share Of $0.48 Reuters Staff\nMay 10 (Reuters) - Syros Pharmaceuticals Inc:\n* SYROS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND HIGHLIGHTS KEY ACCOMPLISHMENTS AND UPCOMING MILESTONES * Q1 REVENUE VIEW $4 MILLION — THOMSON REUTERS I/B/E/S\n* Q1 EARNINGS PER SHARE VIEW $-0.39 — THOMSON REUTERS I/B/E/S\n* SYROS PHARMACEUTICALS - PLAN TO OPEN SINGLE-AGENT, COMBINATION EXPANSION COHORTS IN PHASE 1 TRIAL OF SY-1365 IN MID-2018\n* SYROS - EXPECT TO REPORT INITIAL DATA FROM COMBINATION ARMS OF PHASE 2 TRIAL OF SY-1425, DOSE ESCALATION PORTION OF PHASE 1 TRIAL OF SY-1365 IN Q4 2018\n* SYROS PHARMACEUTICALS - CASH, CASH EQUIVALENTS AND MARKETABLE SECURITIES AS OF MARCH 31, 2018 WERE $121.7 MILLION, VERSUS $72.0 MILLION ON DEC 31, 2017\n* SYROS - BELIEVES EXISTING CASH, CASH EQUIVALENTS, MARKETABLE SECURITIES TO BE SUFFICIENT TO ENABLE CO TO FUND PLANNED OPERATING EXPENSES INTO 2020 Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-05-10T14:38:00.000+03:00", "crawled": "2018-05-10T14:55:15.082+03:00", "highlightTitle": ""}